Who are the top shareholders of the Medicamen Biotec?

The top shareholders of Medicamen Biotec are Shivalik Rasayan Limited with 43.16%, followed by Pharmadanica A/s at 10.54%, and individual investors holding 31.58%. There are no pledged promoter holdings or mutual funds invested in the company, and foreign institutional investors hold a combined 0.22%.

The top shareholders of Medicamen Biotec include Shivalik Rasayan Limited, which holds the largest stake at 43.16%. The highest public shareholder is Pharmadanica A/s, owning 10.54%. Additionally, individual investors collectively hold 31.58% of the shares. There are also 4 foreign institutional investors (FIIs) that hold a combined 0.22% of the company. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

Who are in the management team of Medicamen Biotec?

As of March 2022, the management team of Medicamen Biotec includes Sanjay Bansal (Director), Rahul Bishnoi (Chairman), Ashwani Kumar Sharma (Director), and several independent directors, along with Parul Choudhary as Company Secretary.

As of March 2022, the management team of Medicamen Biotec includes the following individuals:<BR><BR>1. Sanjay Bansal - Director<BR>2. Rahul Bishnoi - Chairman (Non-Executive)<BR>3. Ashwani Kumar Sharma - Director<BR>4. Harish Pande - Independent Director<BR>5. S K Singh - Director<BR>6. Arun Kumar - Independent Director<BR>7. Parul Choudhary - Company Secretary & Compliance Officer<BR>8. Sumita Dwivedi - Independent Director<BR>9. Vimal Kumar Shrawat - Director<BR>10. Sangeeta Bishnoi - Independent Director<BR>11. Ravi Kumar Bansal - Independent Director<BR><BR>This team comprises a mix of directors and independent directors, along with a company secretary responsible for compliance.

What does Medicamen Biotec do?

Medicamen Biotech Ltd is a research-driven pharmaceutical company focused on developing, manufacturing, and marketing finished dosage formulations. As of March 2025, it reported net sales of 30 Cr and a net profit of 2 Cr, with a market cap of Rs 579 Cr.

Overview:<BR>Medicamen Biotech Ltd is a research-led pharmaceutical company engaged in the development, manufacturing, and marketing of finished dosage formulations, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History:<BR>Medicamen Biotech Ltd was incorporated in an unspecified year and has maintained its status as a diversified enterprise. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 30 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 579 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 67.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.22% <BR>Debt-Equity: 0.14 <BR>Return on Equity: 4.09% <BR>Price to Book: 2.73 <BR><BR>Contact Details:<BR>Address: 1506 Chiranjiv Tower 43, Nehru Place New Delhi New Delhi : 110019 <BR>Phone: 91-11-47589500 <BR>Email: cs@medicamen.com <BR>Website: http://www.medicamen.com

Has Medicamen Biotec declared dividend?

Yes, Medicamen Biotech Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of September 19, 2024. Despite the dividend, the company has experienced significant declines in price returns over shorter periods, with a total return of 62.16% over the last 5 years.

Medicamen Biotech Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.22%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -28.9%, the dividend return was 0%, resulting in a total return of -28.9%.<BR><BR>Over the past year, the price return was -11.58%, with a dividend return of 0.21%, leading to a total return of -11.37%.<BR><BR>In the 2-year period, the price return was -38.7%, the dividend return was 0.29%, culminating in a total return of -38.41%.<BR><BR>For the 3-year period, the price return stood at -38.25%, the dividend return was 0.51%, which resulted in a total return of -37.74%.<BR><BR>In the 4-year period, the price return was -21.11%, with a dividend return of 0.73%, leading to a total return of -20.38%.<BR><BR>Over the last 5 years, the price return was 60.54%, the dividend return was 1.62%, resulting in a total return of 62.16%.<BR><BR>Overall, while Medicamen Biotech Ltd has declared a dividend, the total returns over various periods show significant declines in price returns, particularly in the shorter terms, with the most positive performance observed over the 5-year period.

Who are the peers of the Medicamen Biotec?

Peers of Medicamen Biotec include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Kerala Ayurveda, Jenburkt Pharma, Ind-Swift Labs, and Albert David. Medicamen Biotec has below-average growth and the lowest 1-year return among its peers at -16.64%.

Peers: The peers of Medicamen Biotec are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Kerala Ayurveda, Jenburkt Pharma, Ind-Swift Labs., and Albert David.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Medicamen Biotec, Jenburkt Pharma, and Albert David. Below Average management risk is noted at Kerala Ayurveda, Ind-Swift Labs. and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Medicamen Biotec, Divi's Lab., Torrent Pharma, Kerala Ayurveda, Jenburkt Pharma, Ind-Swift Labs., and Albert David. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs., Medicamen Biotec, and Jenburkt Pharma, while Good capital structure is found at Torrent Pharma, and Below Average capital structure is noted at Kerala Ayurveda, Ind-Swift Labs., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the lowest is Medicamen Biotec at -16.64%. Medicamen Biotec's return is significantly lower than the highest peer. Additionally, Ind-Swift Labs. and Albert David have negative six-month returns.

What is the technical trend for Medicamen Biotec?

As of June 2, 2025, Medicamen Biotec's technical trend has shifted to a strong bearish outlook, supported by bearish signals from MACD, Bollinger Bands, and moving averages across multiple time frames.

As of 2 June 2025, the technical trend for Medicamen Biotec has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple time frames. The MACD is bearish on both the weekly and monthly charts, and Bollinger Bands also reflect a bearish trend in both time frames. Daily moving averages confirm a bearish outlook. While the KST shows a mildly bullish signal on the monthly, it is overshadowed by the overall bearish sentiment from other indicators. The Dow Theory indicates a mildly bearish trend on the weekly, and the OBV is also mildly bearish across both weekly and monthly periods. Overall, the technical indicators strongly support a bearish stance.

How big is Medicamen Biotec?

As of 24th July, Medicamen Biotech Ltd has a market capitalization of 539.00 Cr, with net sales of 162.54 Cr and a net profit of 8.70 Cr reported in the latest four quarters. Shareholder's funds are 206.98 Cr, and total assets amount to 292.04 Cr as of March 2024.

As of 24th July, Medicamen Biotech Ltd has a market capitalization of 539.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Medicamen Biotech reported Net Sales of 162.54 Cr and a Net Profit of 8.70 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 206.98 Cr and Total Assets of 292.04 Cr.

When is the next results date for Medicamen Biotec?

Medicamen Biotec will announce its results on 12 August 2025.

Medicamen Biotec will declare its results on 12 August 2025.

Are Medicamen Biotec latest results good or bad?

Medicamen Biotech's latest results show a 30.75% increase in Profit After Tax and a 59.26% rise in consolidated net profit, indicating operational strengths. However, flat net sales, rising interest costs, and decreased liquidity raise concerns about the company's financial health.

Medicamen Biotech's latest results present a mixed picture. On one hand, the company has shown a year-on-year growth in Profit After Tax (PAT) of 30.75%, reaching Rs 4.55 crore, which indicates some operational strengths. Additionally, the consolidated net profit for the quarter ending June 2025 has increased significantly by 59.26% compared to the same quarter last year.<BR><BR>However, there are notable challenges as well. The company reported a flat performance in net sales with a slight decline of 0.02% compared to the previous year, and it faced a dramatic increase in quarterly interest costs, which surged to Rs 1.15 crore. This rise in interest expenses suggests that the company is relying more on borrowing, as indicated by the highest debt-equity ratio of 0.16 times in recent periods. Furthermore, the cash and cash equivalents have decreased to Rs 3.76 crore, marking a low point in liquidity.<BR><BR>In summary, while there are positive signs in profitability, the significant rise in interest costs and declining liquidity raise concerns about the company's financial health moving forward.

How has been the historical performance of Medicamen Biotec?

Medicamen Biotec's historical performance shows a decline in net sales from 179.31 Cr in March 2024 to 162.55 Cr in March 2025, with a drop in operating profit and profit after tax, while total assets and liabilities slightly increased. Cash flow from operating activities remained negative at -6.00 Cr for both years.

Answer:<BR>The historical performance of Medicamen Biotec shows fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Medicamen Biotec's net sales peaked at 179.31 Cr in March 2024 but declined to 162.55 Cr by March 2025. The total operating income followed a similar trend, decreasing from 179.31 Cr in March 2024 to 162.55 Cr in March 2025. The raw material costs also saw a decrease from 104.70 Cr in March 2024 to 90.65 Cr in March 2025, while employee costs increased slightly from 30.07 Cr to 31.87 Cr in the same period. Operating profit (PBDIT) fell from 24.57 Cr in March 2024 to 20.11 Cr in March 2025, reflecting a decline in operating profit margin from 12.4% to 8.53%. Profit before tax decreased from 13.08 Cr to 9.88 Cr, leading to a profit after tax of 6.56 Cr in March 2025, down from 9.49 Cr the previous year. The earnings per share (EPS) also dropped from 8.64 to 5.24. On the balance sheet, total assets increased from 292.04 Cr in March 2024 to 294.32 Cr in March 2025, while total liabilities rose slightly from 292.04 Cr to 294.32 Cr. Cash flow from operating activities remained negative at -6.00 Cr for both March 2024 and March 2025, indicating ongoing challenges in generating cash from operations.

Should I buy, sell or hold Medicamen Biotec?

Is Medicamen Biotec overvalued or undervalued?

As of November 14, 2025, Medicamen Biotec is considered expensive and overvalued with a PE ratio of 58.40 and an EV to EBITDA of 38.85, despite a slight improvement in valuation grade, as evidenced by its poor stock performance of -19.84% year-to-date compared to the Sensex's 8.22% gain.

As of 14 November 2025, Medicamen Biotec's valuation grade has moved from very expensive to expensive, indicating a slight improvement in perceived value. However, the company is still considered overvalued. The key ratios highlight this situation, with a PE ratio of 58.40, an EV to EBITDA of 38.85, and a PEG ratio of 2.88, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Medicamen Biotec's PE ratio stands out against Sun Pharma's 36.49 and Torrent Pharma's 60.06, while its EV to EBITDA ratio is higher than both Sun Pharma and Cipla, which has an attractive EV to EBITDA of 16.08. The company's recent stock performance has been lackluster, with a year-to-date return of -19.84%, contrasting sharply with the Sensex's gain of 8.22% during the same period, further reinforcing the notion that Medicamen Biotec is overvalued in the current market context.

Which are the latest news on Medicamen Biotec?

Why is Medicamen Biotec falling/rising?

As of 04-Dec, Medicamen Biotech Ltd's stock price is 390.25, down 0.19%, and has significantly underperformed the Sensex over various periods, with a year-to-date decline of 23.37% compared to the Sensex's gain of 9.12%. Despite increased investor interest, the stock remains below sector performance and shows mixed short-term momentum.

As of 04-Dec, Medicamen Biotech Ltd's stock price is currently at 390.25, reflecting a decrease of 0.75 or 0.19%. The stock has underperformed compared to the benchmark Sensex, which has shown a slight decline of 0.53% over the past week, while Medicamen's stock has dropped by 5.99% in the same period. <BR><BR>In terms of longer-term performance, the stock has experienced significant declines, with a year-to-date drop of 23.37% compared to the Sensex's gain of 9.12%. Over the past year, Medicamen's stock has fallen by 26.44%, while the Sensex has increased by 5.32%. The three-year performance shows an even steeper decline of 53.66% for Medicamen, contrasting sharply with the Sensex's growth of 35.62%. <BR><BR>Despite these negative trends, there has been a rise in investor participation, with a delivery volume of 37.1k on December 3rd, which is up by 38% against the five-day average. This indicates some level of interest in the stock, although it still remains below the performance of the sector by 0.48%. The stock is trading higher than its 50-day and 100-day moving averages but is lower than its 5-day, 20-day, and 200-day moving averages, suggesting mixed signals regarding its short-term momentum.<BR><BR>Overall, the combination of significant declines in stock performance over various periods and underperformance relative to the benchmark indicates that Medicamen Biotech Ltd's stock is currently falling.